SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC’s Q1 net loss widens to Rs 78.84 crore

07 Aug 2017 Evaluate

Sun Pharma Advanced Research Company (SPARC) has reported results for first quarter ended June 30, 2017.

The company has reported a net loss of Rs 78.84 crore for the quarter under review as against a net loss of Rs 36.14 crore for the same quarter in the previous year. However, total income of the company increased marginally by 0.49% at Rs 24.62 crore for Q1FY18 as compared Rs 24.50 crore for the corresponding quarter previous year.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

144.00 -0.55 (-0.38%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 443.50
Indegene 487.75
CMS Info Systems 312.95
JITF Infralogistics 324.65
Sagility 42.24
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×